Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Pituitary ACTH Hypersecretion (Cushing Disease) Overview
  3. Therapeutics Development
  4. Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) - Overview
  5. Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis
  6. Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics under Development by Companies
  7. Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics under Investigation by Universities/Institutes
  8. Pituitary ACTH Hypersecretion (Cushing Disease) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Pituitary ACTH Hypersecretion (Cushing Disease) - Products under Development by Companies
  13. Pituitary ACTH Hypersecretion (Cushing Disease) - Products under Investigation by Universities/Institutes
  14. Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development
  • Alder Biopharmaceuticals Inc.
  • Corcept Therapeutics Incorporated
  • Cyclacel Pharmaceuticals, Inc.
  • ElexoPharm GmbH
  • Ionis Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Millendo Therapeutics, Inc.
  • Orphagen Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Strongbridge Biopharma plc
  • XOMA Corporation

For more information visit http://www.researchandmarkets.com/research/tw6jds/pituitary_acth

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Endocrine and Metabolic Disorder Drugs, Endocrine and Metabolic Disorder Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Endocrine and Metabolic Disorder Drugs, Endocrine and Metabolic Disorder Drugs